Categories World News
Crowd crush kills 35 children at funfair in Nigeria, police say
December 20, 2024
At least 35 children were killed and six others critically
Categories World News
Pakistan denounces US sanctions on its missile program as ‘discriminatory’
December 20, 2024
Pakistan on Thursday denounced new US sanctions on the country’s
Categories World News
A tale of two Syrians: One finally made it back, another is too fearful to return
December 20, 2024
Ahmad Morjan was desperate to hug his mother for the
Categories World News
Malaysia says it will resume search for missing flight MH370
December 20, 2024
Malaysia has agreed in principle to resume the search for
Categories World News
At least one killed and several embassies damaged in ‘barbaric’ Russian missile barrage on Kyiv, Ukraine says
December 20, 2024
At least one person has been killed and several embassies
Categories Investing
Hempalta Corp. Announces Financial Results for Year Ended September 30, 2024
December 20, 2024
AgTech Company highlights recent 100% purchase of Hemp Carbon Standard platform to advance industrial hemp carbon credits global market opportunity Hempalta Corp. (TSXV:
Categories Investing
Opawica Explorations Inc Begins Field Work in Preparation of Upcoming Drill Campaign at Its Bazooka Property in the Abitibi Gold Belt
December 20, 2024
(TheNewswire) December 19th, 2024 TheNewswire – Vancouver, B.C. Opawica Explorations Inc. (TSXV: OPW) (FSE: A2PEAD) (OTCQB: OPWEF) (the ‘Company’ or ‘Opawica’)
Categories Investing
Forum Comments on Share Price
December 20, 2024
Forum Energy Metals Corp. (TSXV: FMC) (OTCQB: FDCFF) (‘Forum’ or the ‘Company’) announced today that the Company is not aware of any
Categories Investing
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis
December 20, 2024
Cardiol Therapeutics President and CEO, David Elsley PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO,
Categories Investing
RAD 202 receives approval to start Phase 1 therapeutic trial
December 20, 2024
Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This post appeared first on